CNR1 and viral infectious disease: Consistent with these findings, 1 μM pretreatment with the CB1R selective agonist arachidonyl-2′-chloroethylamide (ACEA) did not significantly reduce viral infection (4.76±3.13%, mean±SEM, n = 5 donors) (Figure 1D).